Skip to main content
Top
Published in: Clinical and Experimental Nephrology 9/2019

01-09-2019 | Kidney Transplantation | Original article

Relative hypophosphatemia early after transplantation is a predictor of good kidney graft function

Authors: Kentaro Nakai, Koji Mitsuiki, Yusuke Kuroki, Takehiro Nishiki, Kentaro Motoyama, Toshiaki Nakano, Takanari Kitazono

Published in: Clinical and Experimental Nephrology | Issue 9/2019

Login to get access

Abstract

Background

Phosphate level is a potent independent risk factor for cardiovascular disease and mortality in patients with chronic kidney disease. The association between hypophosphatemia and kidney function in kidney transplant patients is uncertain.

Methods

In total, 90 kidney transplant recipients were divided into two groups: one group of patients with hypophosphatemia and the other group without hypophosphatemia. The recipients with hypophosphatemia were identified as having less than or equal to the lowest quartile of serum phosphate levels at 1-, 3-, and 12-month post-transplant. The cumulative kidney survival rates were calculated for each group using the Kaplan–Meier method, and the adjusted hazard ratio (HR) was calculated using the Cox regression model.

Results

The mean age of patients was 47 years and the median follow-up period was 58 months. During the follow-up period, the following results were demonstrated in 90 transplant patients: graft loss (n = 6), mortality (n = 3). According to the Kaplan–Meier analysis results, the patients with hypophosphatemia demonstrated a significantly lower risk of 30% decline in eGFR compared to those without hypophosphatemia at 1- and 3-month post-transplant, but not at 12-month post-transplant. After adjusting for confounding factors, hypophosphatemia at 1- and 3-month post-transplant was an independent predictor of good kidney survival (HR 0.31, 95% CI 0.10–0.82 and HR 0.31, 95% CI 0.07–0.92, respectively).

Conclusions

Our findings suggest that hypophosphatemia during the first 3 months after kidney transplantation was associated with better kidney survival.
Literature
1.
go back to reference Tentori F, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52(3):519–30.CrossRefPubMed Tentori F, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52(3):519–30.CrossRefPubMed
2.
go back to reference Taniguchi M, et al. Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. Ther Apher Dial. 2013;17(2):221–8.CrossRefPubMed Taniguchi M, et al. Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. Ther Apher Dial. 2013;17(2):221–8.CrossRefPubMed
3.
go back to reference Kestenbaum B, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16(2):520–8.CrossRefPubMed Kestenbaum B, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16(2):520–8.CrossRefPubMed
4.
go back to reference Nakai K, et al. Parathyroid enlargement at dialysis initiation in patients with chronic kidney diseases. Ther Apher Dial. 2013;17(1):24–9.CrossRefPubMed Nakai K, et al. Parathyroid enlargement at dialysis initiation in patients with chronic kidney diseases. Ther Apher Dial. 2013;17(1):24–9.CrossRefPubMed
5.
go back to reference Evenepoel P, et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol. 2008;3(6):1829–36.CrossRefPubMedPubMedCentral Evenepoel P, et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol. 2008;3(6):1829–36.CrossRefPubMedPubMedCentral
6.
go back to reference Kawarazaki H, et al. Natural history of mineral and bone disorders after living-donor kidney transplantation: a one-year prospective observational study. Ther Apher Dial. 2011;15(5):481–7.CrossRefPubMed Kawarazaki H, et al. Natural history of mineral and bone disorders after living-donor kidney transplantation: a one-year prospective observational study. Ther Apher Dial. 2011;15(5):481–7.CrossRefPubMed
7.
go back to reference Taniguchi M, et al. Persistent hyperparathyroidism in renal allograft recipients: Vitamin D receptor, calcium-sensing receptor, and apoptosis. Kidney Int. 2006;70(2):363–70.CrossRefPubMed Taniguchi M, et al. Persistent hyperparathyroidism in renal allograft recipients: Vitamin D receptor, calcium-sensing receptor, and apoptosis. Kidney Int. 2006;70(2):363–70.CrossRefPubMed
8.
go back to reference Matsuo S, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92.CrossRefPubMed Matsuo S, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92.CrossRefPubMed
9.
go back to reference Masutani K, et al. Usefulness of 3-month protocol biopsy of kidney allograft to detect subclinical rejection under triple immunosuppression with basiliximab: a single center experience. Clin Exp Nephrol. 2011;15(2):264–8.CrossRefPubMed Masutani K, et al. Usefulness of 3-month protocol biopsy of kidney allograft to detect subclinical rejection under triple immunosuppression with basiliximab: a single center experience. Clin Exp Nephrol. 2011;15(2):264–8.CrossRefPubMed
10.
go back to reference Yotsueda R, et al. Cardiothoracic ratio and all-cause mortality and cardiovascular disease events in hemodialysis patients: the Q-cohort study. Am J Kidney Dis. 2017;70(1):84–92.CrossRefPubMed Yotsueda R, et al. Cardiothoracic ratio and all-cause mortality and cardiovascular disease events in hemodialysis patients: the Q-cohort study. Am J Kidney Dis. 2017;70(1):84–92.CrossRefPubMed
11.
go back to reference Arase H, et al. Modified creatinine index and risk for cardiovascular events and all-cause mortality in patients undergoing hemodialysis: The Q-Cohort study. Atherosclerosis. 2018;275:115–23.CrossRefPubMed Arase H, et al. Modified creatinine index and risk for cardiovascular events and all-cause mortality in patients undergoing hemodialysis: The Q-Cohort study. Atherosclerosis. 2018;275:115–23.CrossRefPubMed
12.
go back to reference Van Londen M, et al. Post-transplant hypophosphatemia and the risk of death-censored graft failure and mortality after kidney transplantation. Clin J Am Soc Nephrol. 2017;12(8):1301–10.CrossRefPubMedPubMedCentral Van Londen M, et al. Post-transplant hypophosphatemia and the risk of death-censored graft failure and mortality after kidney transplantation. Clin J Am Soc Nephrol. 2017;12(8):1301–10.CrossRefPubMedPubMedCentral
13.
go back to reference Schaeffner ES, Födinger M, Kramar R, Sunder-Plassmann G, Winkelmayer WC. Prognostic associations of serum calcium, phosphate and calcium phosphate concentration product with outcomes in kidney transplant recipients. Transpl Int. 2007;20(3):247–55.CrossRefPubMed Schaeffner ES, Födinger M, Kramar R, Sunder-Plassmann G, Winkelmayer WC. Prognostic associations of serum calcium, phosphate and calcium phosphate concentration product with outcomes in kidney transplant recipients. Transpl Int. 2007;20(3):247–55.CrossRefPubMed
14.
go back to reference Merhi B, et al. Serum phosphorus and risk of cardiovascular disease, all-cause mortality, or graft failure in kidney transplant recipients: an ancillary study of the FAVORIT trial cohort. Am J Kidney Dis. 2017;70(3):377–85.CrossRefPubMedPubMedCentral Merhi B, et al. Serum phosphorus and risk of cardiovascular disease, all-cause mortality, or graft failure in kidney transplant recipients: an ancillary study of the FAVORIT trial cohort. Am J Kidney Dis. 2017;70(3):377–85.CrossRefPubMedPubMedCentral
15.
go back to reference Chang WX, et al. The impact of normal range of serum phosphorus on the incidence of end-stage renal disease by a propensity score analysis. PLoS ONE. 2016;11(4):e0154469.CrossRefPubMedPubMedCentral Chang WX, et al. The impact of normal range of serum phosphorus on the incidence of end-stage renal disease by a propensity score analysis. PLoS ONE. 2016;11(4):e0154469.CrossRefPubMedPubMedCentral
16.
go back to reference Zoccali C, et al. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol. 2011;22(10):1923–30.CrossRefPubMedPubMedCentral Zoccali C, et al. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol. 2011;22(10):1923–30.CrossRefPubMedPubMedCentral
17.
go back to reference Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol. 2006;1(4):825–31.CrossRefPubMed Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol. 2006;1(4):825–31.CrossRefPubMed
18.
go back to reference Jeon HJ, et al. Association of serum phosphorus concentration with mortality and graft failure among kidney transplant recipients. Clin J Am Soc Nephrol. 2017;12(4):653–62.CrossRefPubMedPubMedCentral Jeon HJ, et al. Association of serum phosphorus concentration with mortality and graft failure among kidney transplant recipients. Clin J Am Soc Nephrol. 2017;12(4):653–62.CrossRefPubMedPubMedCentral
19.
go back to reference Okumi M, et al. Cardiovascular disease in kidney transplant recipients: Japan Academic Consortium of Kidney Transplantation (JACK) cohort study. Clin Exp Nephrol. 2018;22(3):702–9.CrossRefPubMed Okumi M, et al. Cardiovascular disease in kidney transplant recipients: Japan Academic Consortium of Kidney Transplantation (JACK) cohort study. Clin Exp Nephrol. 2018;22(3):702–9.CrossRefPubMed
20.
go back to reference Matsushita K, et al. Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate. Kidney Int. 2016;90(5):1109–14.CrossRefPubMed Matsushita K, et al. Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate. Kidney Int. 2016;90(5):1109–14.CrossRefPubMed
21.
go back to reference Chang WX, et al. Predictors and the subsequent risk of end-stage renal disease—usefulness of 30% decline in estimated GFR over 2 years. PLoS ONE. 2015;10(7):e0132927.CrossRefPubMedPubMedCentral Chang WX, et al. Predictors and the subsequent risk of end-stage renal disease—usefulness of 30% decline in estimated GFR over 2 years. PLoS ONE. 2015;10(7):e0132927.CrossRefPubMedPubMedCentral
22.
go back to reference Coresh J, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311(24):2518–31.CrossRefPubMedPubMedCentral Coresh J, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311(24):2518–31.CrossRefPubMedPubMedCentral
23.
go back to reference Segawa H, et al. Correlation between hyperphosphatemia and type II Na–Pi cotransporter activity in klotho mice. Am J Physiol Renal Physiol. 2007;292(2):F769–F779779.CrossRef Segawa H, et al. Correlation between hyperphosphatemia and type II Na–Pi cotransporter activity in klotho mice. Am J Physiol Renal Physiol. 2007;292(2):F769–F779779.CrossRef
24.
go back to reference Nakai K, Komaba H, Fukagawa M. New insights into the role of fibroblast growth factor 23 in chronic kidney disease. J Nephrol. 2010;23(6):619–25.PubMed Nakai K, Komaba H, Fukagawa M. New insights into the role of fibroblast growth factor 23 in chronic kidney disease. J Nephrol. 2010;23(6):619–25.PubMed
Metadata
Title
Relative hypophosphatemia early after transplantation is a predictor of good kidney graft function
Authors
Kentaro Nakai
Koji Mitsuiki
Yusuke Kuroki
Takehiro Nishiki
Kentaro Motoyama
Toshiaki Nakano
Takanari Kitazono
Publication date
01-09-2019
Publisher
Springer Singapore
Published in
Clinical and Experimental Nephrology / Issue 9/2019
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-019-01756-z

Other articles of this Issue 9/2019

Clinical and Experimental Nephrology 9/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.